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 Introduction 
 Infections caused by multi-resistant gram-positive 
pathogens represent a major burden on healthcare. If risk 
factors for methicillin-resistant staphylococcus aureus 
(MRSA) are present, vancomycin is indicated  [1] . Espe-
cially for implant-associated infections (e.g. infections of 
total endoprothesis, prosthetic valve endocarditis), the 
combination therapy with rifampicin and vancomycin is 
recommended  [1] . However, linezolid is often used in 
case of resistance or contraindication to vancomycin or if 
sequential therapy is indicated  [1] . Due to the long-last-
ing treatment duration of implant-associated infections, 
the high oral bioavailability of linezolid (approximately 
100%)  [2] is an attractive oral alternative to intravenous 
glycopeptides.
 Pharmacodynamic kill characteristics of linezolid are 
concentration-dependent with time-dependence. There-
fore, AUC/MIC >100 (where, AUC = area under the an-
tibiotic concentration-time curve for 24 h, MIC = mini-
mal inhibitory concentration) is proposed as pharmaco-
kinetic index predictive for efficacy  [3] . Due to the MIC 
values of pathogens, trough concentrations  ≥ 2 mg/l and/
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 Abstract 
 Linezolid is a valuable treatment option for treating infec-
tions caused by multi-resistant gram-positive pathogens. 
Lack of effective linezolid levels due to the co-administration 
of rifampicin has been described in healthy subjects. How-
ever, the clinical significance of this potential drug interac-
tion (DI) for critically ill patients is still unclear. This was a 
retrospective analysis of 3 critically ill patients with the com-
bination therapy of linezolid and rifampicin or rifampicin 
pre-treatment. Despite increasing the dose of linezolid, the 
majority of observed linezolid trough concentrations in all 3 
patients were below 2 mg/l. Furthermore, linezolid trough 
concentrations remained below 2 mg/l after discontinuation 
of rifampicin. This potential DI between linezolid and rifam-
picin could lead to treatment failure. Therefore, we strongly 
recommend that linezolid serum concentrations be moni-
tored in patients with rifampicin co-administration or rifam-
picin pretreatment.  © 2016 S. Karger AG, Basel 
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or AUC 24 >160–200 mg * h/l should be achieved to inhib-
it the growth of 90% of organisms (MIC90) for staphylo-
cocci  [3] .
 Recently, it has been demonstrated that linezolid plas-
ma exposure might significantly vary in some patient 
populations  [4] and in those receiving polypharmacy  [5] . 
Co-administrations of drugs such as clarithromycin, ami-
odarone, amlodipine, or omeprazole may be responsible 
for linezolid overexposure, which could favor drug-relat-
ed adverse events  [5] . In contrast, lack of effective line-
zolid concentrations due to the co-administration of ri-
fampicin is described in healthy subjects, and this could 
lead to treatment failure  [2, 6] . However, the clinical sig-
nificance of this potential drug interaction (DI) for criti-
cally ill patients is still unclear.
 The objective of this clinical case study was to report 
about linezolid serum concentrations in critically ill pa-
tients with rifampicin co-administration or rifampicin 
pretreatment.
 Methods 
 This was a retrospective analysis of critically ill patients who 
were treated with the combination therapy of linezolid and rifam-
picin or rifampicin pretreatment due to suspected or proven 
MRSA infection and therapeutic drug monitoring (TDM) of line-
zolid. Ethical approval was obtained from the ethics committees 
(Ludwig-Maximilian-Universität München, München, Germany; 
Universität Ulm, Ulm, Germany). The ethics committee waived 
the need for patient consent due to the retrospective nature of the 
study. Blood samples were collected just before the initiation of the 
linezolid infusion (trough in serum, steady-state; C min , ss) and 
within half an hour after linezolid infusion at 3 or 4 h (peak in se-
rum, steady-state; C max , ss). Linezolid trough and peak concentra-
tions in serum were measured by a validated high-performance 
liquid chromatography with ultraviolet detection, as has been pre-
viously described in detail  [7] .
 Results 
 Three critically ill patients with linezolid and rifampi-
cin co-administration or rifampicin pretreatment were 
analyzed. In total, 22 blood samples were collected.
 Case 1 
 A 65-year-old patient (weight 65 kg, height 165 cm) 
with a history of bowel syndrome and pulmonary emphy-
sema was hospitalized because of subarachnoid hemor-
rhage with concomitant obstructive hydrocephalus. The 
patient underwent successful clipping of a posterior infe-
rior cerebellar artery aneurysm, and an intraventricular 
catheter (IVC) was placed for the management of hydro-
cephalus. Treatment with ceftriaxone and clindamycin 
was initiated because of aspiration pneumonia and bone 
infection prophylaxis for 7 days. On day 7, the patient de-
veloped an IVC-associated ventriculitis. The IVC was re-
placed and empirical antibiotic therapy was commenced 
with vancomycin (2 times daily, targeting serum trough 
concentration of 15–20 mg/ml) and meropenem (2 g 
3 times daily). No pathogens could be isolated from the 
cerebrospinal fluid (CSF) sample. On day 9, a combina-
tion therapy with rifampicin (600 mg once a day) for 
7 days was commenced because of a deteriorating condi-
tion. On day 15, vancomycin was withdrawn because of 
an increase in serum creatinine levels (from 0.8 to 1.4 mg/l) 
and replaced by linezolid (600 mg 2 times daily). Rifam-
picin was replaced by fosfomycin (5 g 3 times daily) be-
cause of persisting inflammatory response and high cell 
count in the CSF. In addition, aspiration pneumonia was 
treated with moxifloxacin (400 mg once a day) for 7 days 
because of progressive pulmonary infiltrates. On day 16, 
the patient developed acute kidney injury probably due to 
X-ray contrast medium and was treated with continuous 
veno-venous hemodialysis for 6 days (dialysate flow 2,000 
ml, blood flow 100 ml). TDM of linezolid was started. On 
days 17 and 19, serum trough concentrations of linezolid 
were undetectable (<0.5 mg/l). Linezolid serum concen-
trations at 7 h were 0.5 mg/l ( table 1 ). On day 19, IVC-
associated ventriculitis was cured; however, antibiotic 
therapy was continued until day 27 as recommended in 
guidelines. On days 21, 26 and 27, serum trough concen-
trations of linezolid remained below 2.2 mg/l ( table 1 ). Se-
rum peak concentrations of linezolid increased but re-
mained below 10 mg/l. The IVC was removed on day 35. 
The patient was discharged from the hospital for further 
rehabilitation on day 44 ( table 1 ;  fig. 1 ).
 Case 2 
 A 72-year-old patient (weight 90 kg, height 168 cm) 
with a history of coronary heart disease, peripheral arte-
rial disease and kidney disease was hospitalized because 
of shoulder empyema. The patient underwent humeral 
head resection. On day 3 of treatment with ciprofloxa-
cin (400 mg 2 times daily), linezolid (600 mg 2 times 
daily) and rifampicin (600 mg 2 times daily) were initi-
ated due to MRSA growing in the blood cultures after 
pretreatment with ampicillin/sulbactam. On day 5, cip-
rofloxacin was stopped due to the results of resistance 
testing. TDM of linezolid was started. Serum trough 
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6 and 10, despite dose increases to 1,800 mg/24 h ( ta-
ble 1 ). On days 4 and 6, serum peak concentrations of 
linezolid were 8.0 and 11.7 mg/l, respectively ( table 1 ). 
On day 12, intravenous linezolid was switched to oral 
linezolid (1,800 mg/24 h). Serum trough concentrations 
of linezolid remained below 1 mg/l on days 19 and 23 
( table 1 ). On day 24, linezolid was increased to 2,700 
mg/24 h. Peak serum concentration of linezolid (1 h af-
ter oral administration) was 5 mg/l ( table 1 ). On day 25, 
linezolid was discontinued due to microbiological cure 
15 16 17 18 19 20 21 22 23 24 25 26 27
Day of hospitalisation



























2 mg/l 10 mg/l
 Fig. 1. Linezolid serum concentrations case 
1 as example. Therapeutic serum concen-
trations of linezolid are expected to be be-
tween 4 and 10 mg/l using standard dosing 
(600 mg 2 times daily). Due to the MIC val-
ues of pathogens, trough concentrations 
 ≥ 2  mg/l and/or AUC 24 >160–200 mg * h/l 
should be achieved to inhibit the growth of 
90% of organisms (MIC90) for staphylo-
cocci  [3] . Linezolid trough concentrations 
were even below 2 mg/l 13 days after rifam-
picin discontinuation. 
Table 1.  Linezolid doses and corresponding linezolid serum concentrations in 3 critically ill patients with rifampicin pretreatment (case 
1) or rifampicin co-administration (cases 2 and 3)















3 2 × 600 4 Day 3 without rifampicin – <0.5 0.5 (7 h after infusion start)
5 2 × 600 4 Day 5 without rifampicin – <0.5 0.5 (7 h after infusion start)
7 2 × 600 4 Day 7 without rifampicin – 2.1 3.3
12 2 × 600 4 Day 12 without rifampicin – 2.0 3.9
13 2 × 600 4 Day 13 without rifampicin – <0.5 5.2
Case 2
2 2 × 600 0.5 2 × 600 IV 0.6 8.0
4 3 × 600 0.5 2 × 600 IV 4.1–1.5 h too early 11.7
8 3 × 600 0.5 2 × 600 IV 0.9 ND
21 3 × 600 Oral 2 × 600 IV 0.9 ND
25 3 × 600 Oral 2 × 600 IV 0.8 ND
26 3 × 900 Oral 2 × 600 Oral ND 5
Case 3
2 2 × 600 0.5 2 × 300 Oral 0.5 ND
3 3 × 600 0.5 2 × 300 Oral 0.5 ND
7 3 × 600 Oral 2 × 450 Oral 1.9 6.5




















   
   
   
   
   
   
   
   
   
   
   


























after knee puncture. Antibiotic therapy was terminated 
on day 25. The patient was discharged from the hospital 
on day 26.
 Case 3 
 A 77-year-old patient (weight 107 kg, height 178 cm) 
with a history of diabetes and heart disease was hospital-
ized because of total endoprothesis infection after knee 
anthroplasty surgery. The patient underwent endoproth-
esis removal and a spacer was placed. Staphylococcus epi-
dermidis was isolated from a knee puncture. Treatment 
with vancomycin (1 g 2 times daily) and rifampicin (600 
mg 2 times daily) was initiated. On day 18, vancomycin 
was switched to linezolid (600 mg 2 times daily). Rifam-
picin was reduced to 300 mg 2 times daily. Linezolid 
TDM was started. Serum concentrations of linezolid were 
measured on days 19 and 20. On day 21, linezolid was 
switched to oral linezolid and increased to 1,800 mg/24 h 
because of linezolid serum concentrations below 1.0 mg/l 
( table 1 ). On day 25, linezolid serum trough concentra-
tion 30 min before administration and 1 h after adminis-
tration were 1.9 and 6.5 mg/l, respectively ( table 1 ). On 
day 25, rifampicin was increased to 450 mg 2 times daily. 
The patient was discharged from the hospital on day 31.
 Discussion 
 In these clinical case studies, we observed an increased 
linezolid clearance in critically ill patients with rifampicin 
co-administration as well as rifampicin pretreatment. Al-
though trough serum concentrations of linezolid are sup-
posed to be between 4 and 6 mg/l  [3] , the majority of ob-
served trough serum concentrations of linezolid in all 3 
patients were below the MIC of susceptible MRSA 
(<2 mg/l)  [3] , despite increasing the dose of linezolid in 2 
patients (see Results). Moreover, linezolid trough con-
centrations were even below 2 mg/l 13 days after rifampi-
cin discontinuation in case 1 (see Results;  table 1 ).
 Rifampicin is able to induce several hepatic enzymes 
like cytochrome 450 enzymes (CYP) as well as carrier 
proteins like P-glycoprotein (P-gp). Co-administration 
of rifampicin and other drugs that are transported by 
P-gp or metabolized by the hepatic CYP system can lead 
to clinical relevant DI due to the induction of enzymes in 
shared metabolic pathways. Therefore, rifampicin has a 
high potential for pharmacokinetic interactions with oth-
er drugs  [8] .
 Linezolid is primarily metabolized by the oxidation of 
the morpholine ring, which results in 2 inactive major 
metabolites. Urinary elimination accounts for 35% of the 
parent drug  [9] . However, the enzyme system or oxidants 
formation in vivo have not been elucidated yet  [10] . A 
discussion on the participation of CYP in the metabolic 
pathway  led to controversial results  [5, 9, 10, 11] .
 Recently, interactions between rifampicin and linezol-
id have been reported, in which linezolid serum concen-
trations were reduced  [6, 11–13] . Rifampicin was shown 
to cause about 30% reduction of linezolid exposure in 
healthy subjects  [6, 11] . Yet, in our case study, linezolid 
trough concentrations are even lower. Zoller et al. [4] de-
scribed a high variability of linezolid serum concentra-
tions in a heterogeneous group of critically ill patients. 
One possible reason could be that linezolid serum expo-
sure might significantly vary in some patient populations 
such as critically ill patients. Indeed, decreased linezolid 
concentrations by 40–60% were described in a critically 
ill patient  [12] and decreased linezolid concentrations by 
87–94% in 2 non-critically ill patients  [13] .
 Moreover, several retrospective observational studies 
described a lower incidence of hematological adverse 
events among patients receiving rifampicin and linezolid 
compared to patients receiving linezolid alone. This 
might indicate clinical significance of this DI. Soriano et 
al. [14] investigated the effects of rifampicin on hemato-
logical adverse events induced by linezolid in a compara-
tive study. The co-administration of rifampicin was as-
sociated with a lower risk of thrombocytopenia. Likewise, 
Legout et al. [15] described a lower risk of anemia in pa-
tients with bone and joint infections if they received ri-
fampicin and linezolid compared to patients receiving li-
nezolid alone or in combination with other drugs. On the 
contrary, differences in clinical success rates were not ob-
served. Pea et al. [5] investigated the toxicity of long-term 
treatment with linezolid. Patients receiving rifampicin 
and linezolid vs. receiving linezolid alone had significant-
ly lower trough concentrations (C min 1.37 vs. 3.71 mg/l) 
or AUC 24 (123.33 vs. 212.77 mg * h/l). Furthermore, there 
was a lower risk of thrombocytopenia (0 vs. 51.4%). Con-
sequently, rifampicin seemed to display a protective effect 
against hematological toxicity. More important, treat-
ment failure was observed more often in the rifampicin-
linezolid group. Therefore, Pea et al. [5] concluded that 
there is no benefit of the co-administration that justifies 
the risk of insufficient dosing and therefore potential an-
tibiotic treatment failure of linezolid. However, the clini-
cal significance of this potential interaction has not yet 
been established and the mechanism needs further re-
search. The mechanism of the pharmacokinetic DI be-




















   
   
   
   
   
   
   
   
   
   
   





















 Decreased Linezolid Serum Concentrations 




lism induction. Because DI can also be observed after ri-
fampicin pretreatment, induction of protein synthesis 
would be most plausible, but the mechanism is found to 
result in controversial outcomes  [6, 11] .
 Conclusions 
 Our clinical case studies support clinical significance 
of this potential DI between linezolid and rifampicin for 
critically ill patients, even if rifampicin is already discon-
tinued. We observed sub-therapeutic linezolid serum 
concentrations in patients with rifampicin co-adminis-
tration as well as rifampicin pretreatment. Although de-
creased linezolid concentrations in healthy subjects are 
already described in the summary of product character-
istics of linezolid  [2] , recommendations with regard to 
patient management are not available yet. The decrease 
in linezolid concentrations could be related to induction 
of metabolism by rifampicin but the mechanism of this 
potential DI is still not understood.
 Clinicians should be aware of this potential interaction 
that could lead to antibiotic treatment failure of linezolid. 
These clinical case studies emphasize the value and need 
of monitoring linezolid serum concentrations with ri-
fampicin co-administration and pretreatment. Further 
investigation is needed to assess the clinical significance 
of the combination therapy.
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